[Featured Stock] Genofocus Rises Amid COVID-19 Resurgence... "Producing Essential Enzymes for Diagnostic Kits"

Recently, with the resurgence of the novel coronavirus infection (COVID-19), Xenofocus, which produces the key enzyme for COVID-19 diagnostic kits, is showing strong performance.

As of 2:40 PM on the 19th, Xenofocus was trading at 3,305 KRW, up 170 KRW (5.42%) compared to the previous trading day.

According to the Korea Disease Control and Prevention Agency, the number of COVID-19 hospitalized patients has increased more than ninefold over the past four weeks. The number of domestic COVID-19 hospitalizations rose sharply from 145 in the second week of July to 1,357 in the second week of August. This is the highest number of hospitalized patients this year.

As a result, demand for COVID-19 self-test diagnostic kits is surging. Production factories have run out of inventory and are operating at full capacity. Diagnostic kit manufacturers are reportedly facing difficulties in supplying products, with delivery reservations for next week's supply already completed.

Xenofocus develops and produces 'Proteinase K,' an essential enzyme used in COVID-19 diagnostic kits. Proteinase K is a special enzyme used not only in COVID-19 but also in various diagnostic kits and nucleic acid extraction kits. It is characterized by maintaining high activity even in environments containing chelating agents, surfactants, and high concentrations of salts.